je.st
news
Tag: ligand
Craig Hallum Reiterates Buy Rating for Ligand Pharmaceuticals
2015-05-24 10:58:48| Biotech - Topix.net
's stock had its "buy" rating restated by investment analysts at Craig Hallum in a note issued to investors on Saturday. They currently have a $105.00 target price on the biotechnology company's stock, up from their previous target price of $90.00.
Tags: buy
rating
craig
pharmaceuticals
Ligand Pharmaceuticals' Shares Could Hit Triple Digits With Forward Guidance And 2015 Catalysts
2015-05-16 22:15:01| Biotech - Topix.net
Ligand Pharmaceuticals , a favorite drug/biotech company of mine, recently reported its first quarter earnings. The strong earnings were enough to send shares up as high as $88.35 on Monday.
Tags: hit
forward
shares
guidance
Ligand Earns Milestone from SAGE Therapeutics for SAGE-547
2015-04-22 21:34:03| Biotech - Topix.net
Ligand Pharmaceuticals Incorporated today announced that it has earned a $500,000 milestone payment from SAGE Therapeutics relating to the treatment of the first patient in SAGE's Phase 3 open-label expanded access protocol, designated Study 302. Study 302 is designed to offer SAGE-547 to patients affected by super-refractory status epilepticus and to evaluate the safety of SAGE-547 in patients with SRSE.
Tags: sage
milestone
earns
therapeutics
Kinetic Ligand Binding And 3D Tumor Invasion Technologies To Assess Drug Residence Time And Anti-metastatic Effects
2015-04-17 17:03:22| drugdiscoveryonline Downloads
Metastasis, the spread of cancer cells from the original tumor to secondary locations within the body, is linked to approximately 90% of cancer deaths. The expression of chemokine receptors, such as CXCR4 and CCR7, is tightly correlated with the metastatic properties of breast cancer cells. In vivo, neutralizing the interaction of CXCR4 and its known ligand, SDF1-α (CXCL12), significantly impaired the metastasis of breast cancer cells and cell migration.
Tags: time
effects
drug
technologies
Ligand Pharmaceuticals: Biotech's Jack Of All Trades
2015-03-26 00:46:06| Biotech - Topix.net
"We do early-stage development, and we aim to partner early," said Matt Foehr, president and chief operating officer. "We keep a flat operating structure, and we enjoy royalties on the back."
Tags: jack
trades
pharmaceuticals
ligand